Lisa M. Broad, Stacy J. Keding and Maria-Jesus Blanco Pages 1431 - 1441 ( 11 )
As last year marked the tenth anniversary of the cloning of TRPV1, no attenuation has been observed in the intense interest surrounding this ion channel by both academic labs and pharmaceutical companies alike. Patent searches provide an extensive list of novel TRPV1 antagonists generated within the last 7 years, while literature searches reveal a diverse collection of TRPV1 antagonists that have progressed into pre-clinical in vivo profiling and even clinical development. This review serves to summarize the current knowledge of TRPV1 and TRPV1 antagonists as pain therapeutics and to highlight how use of divergent TRPV1 antagonists is helping to further define the physiological and pathological role of TRPV1 and the scope for TRPV1 antagonist therapies.
TRPV1, cloning, antagonists, inflammatory, pain therapeutics
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285 USA.